肺癌与气道肿瘤的隆突重建:长期结果
该研究回顾了单中心20年间41例因非小细胞肺癌(NSCLC)或原发性气道肿瘤行隆突切除重建的患者,R0切除率达97.5%,30天死亡率为7.3%,主要并发症率为24.3%,NSCLC与气道肿瘤的5年总生存率分别为44.5%和76.2%。结论认为隆突重建是肿瘤学可靠的手术,在合适选择的患者中可获得良好的长期结果,并应尽可能采用保留肺实质的技术。
要点
- 隆突切除重建在NSCLC和气道肿瘤中可实现97.5%的完全切除率。
- 术后30天死亡率为7.3%,主要并发症率为24.3%。
- NSCLC患者5年总生存率为44.5%,气道肿瘤为76.2%。
核心结论
- 隆突重建是复杂但肿瘤学可靠的手术,在合适选择的患者中可获得良好的长期结果。
- 手术应尽可能包含保留肺实质的技术,在不影响切除彻底性的前提下保留健康肺组织。
研究设计与样本
- 单中心20年回顾性经验,共41例患者因NSCLC(n=32)或原发性气道肿瘤(n=9)行隆突切除重建。
- 手术方式包括右全肺袖状切除19例、左全肺袖状切除6例、孤立隆突切除4例、右肺上叶袖状切除12例。
- 8例需要上腔静脉置换,4例孤立隆突重建使用了体外膜氧合(ECMO),9例接受了新辅助化疗。
主要发现
- 完全切除(R0)率为97.5%。
- 术后30天死亡率为7.3%(n=3),主要并发症率为24.3%(n=10)。
- 气道并发症7例,包括2例吻合口瘘和5例需扩张和支架置入的吻合口狭窄;其他主要并发症包括1例食管胸膜瘘、1例肺炎和1例肺水肿。
- NSCLC患者中26例为病理III期、6例为病理II期;总复发率为34.2%(n=13),NSCLC为41.3%(n=12),气道肿瘤为11.1%(n=1)。
- 3年和5年总生存率分别为56.1%(NSCLC 50.8%,气道肿瘤76.2%)和50.5%(NSCLC 44.5%,气道肿瘤76.2%);3年和5年无病生存率分别为61.7%(NSCLC 55.2%,气道肿瘤85.7%)和55.5%(NSCLC 48.3%,气道肿瘤85.7%)。
临床怎么用
- 对经选择的NSCLC或气道肿瘤侵犯隆突患者,可考虑行隆突切除重建以实现肿瘤学根治。
- 术中应尽可能采用保留肺实质的技术,在不影响切除彻底性的前提下保留健康肺组织。
- 需重视气道吻合口并发症的监测与处理,包括吻合口瘘和狭窄。
局限性
- 单中心回顾性研究,样本量较小(41例),结果需谨慎外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resection and reconstruction of the carina infiltrated by non-small cell lung cancer (NSCLC) or an airway tumor is a technically demanding operation allowing oncologic radical treatment. Hereby we report the results of a 20-year experience from a high-volume center. METHODS: Carinal resection was performed in 41 patients for NSCLC (n = 32) or primary airway tumor (n = 9). Right tracheal-sleeve pneumonectomy was performed in 19 patients, left tracheal-sleeve pneumonectomy in 6, isolated carinal resection in 4, and right tracheal-sleeve upper lobectomy in 12. Superior vena cava replacement was required in 8 patients. Extracorporeal membrane oxygenation was used in 4 patients undergoing isolated carinal reconstruction. Nine patients received neoadjuvant chemotherapy. RESULTS: Complete resection (R0) was achieved in 97.5% of patients. Postoperative 30-day mortality was 7.3% (n = 3). The major complication rate was 24.3% (n = 10). There were 7 airway complications, consisting of 2 anastomotic fistulas and 5 anastomotic stenoses requiring dilatation and stenting; other major complications included 1 esophageal-pleural fistula, 1 pneumonia, and 1 pulmonary edema. Among the 32 NSCLC patients, 26 were pathologic stage III, and 6 were pathologic stage II. The recurrence rate was 34.2% (n = 13) and was 41.3% (n = 12) in NSCLC and 11.1% (n = 1) in airway tumors. The 3- and 5-year overall survival (Kaplan-Meier) was 56.1% (NSCLC, 50.8%; airway, 76.2%) and 50.5% (NSCLC, 44.5%; airway, 76.2%), respectively. Disease-free survival was 61.7% (NSCLC, 55.2%; airway, 85.7%) at 3 years and 55.5% (NSCLC, 48.3%; airway, 85.7%) at 5 years. CONCLUSIONS: Carinal reconstruction for lung and airway tumors resection is a complex, oncologically reliable procedure allowing good long-term results in adequately selected patients. Wherever possible, these operations should include parenchymal-sparing techniques allowing healthy lung tissue being spared without compromising the radicality of the resection.
引用
- D'Andrilli A, Trabalza Marinucci B, Ciccone AM, et al. Carinal Reconstruction for Lung Cancer and Airway Tumors: Long-term Results. Ann Thorac Surg. 2024. PMID: 39447856. doi:10.1016/j.athoracsur.2024.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。